{"id":53912,"date":"2023-02-14T18:05:15","date_gmt":"2023-02-14T17:05:15","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/janux-therapeutics-to-participate-in-novel-io-panel-discussion-at-cowens-43rd-annual-health-care-conference\/"},"modified":"2023-02-14T18:05:15","modified_gmt":"2023-02-14T17:05:15","slug":"janux-therapeutics-to-participate-in-novel-io-panel-discussion-at-cowens-43rd-annual-health-care-conference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/janux-therapeutics-to-participate-in-novel-io-panel-discussion-at-cowens-43rd-annual-health-care-conference\/","title":{"rendered":"Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen’s 43rd Annual Health Care Conference"},"content":{"rendered":"
\n

SAN DIEGO–(BUSINESS WIRE)–$JANX<\/a>—Janux Therapeutics, Inc.<\/a> (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will participate in a Novel Immuno-Oncology (IO) panel discussion at Cowen’s 43rd Annual Health Care Conference and be available for 1×1 meetings from March 6 to 8, 2023 in Boston. Details of the presentations are as follows:\n<\/p>\n

<\/a><\/p>\n

\nCowen’s 43rd Annual Health Care Conference
\n
<\/b>Date: Monday, March 6
\n
Time: 9:10am to 10:10am Eastern Time
\n
Location: Boston Marriott Copley Place
\n
Forum: Novel IO Panel\n<\/p>\n

\nPresentations and subsequent archived replay may be accessed via the Investors & Media section of Janux\u2019s website<\/a>. An archived replay of the webcast will be available on the website for approximately 90 days following the presentation.\n<\/p>\n

\nAbout Janux Therapeutics<\/b>\n<\/p>\n

\nJanux Therapeutics is an innovative clinical-stage biopharmaceutical company developing next-generation therapeutics based on applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms to better treat patients suffering from cancer. Janux\u2019s initial focus is on developing a novel class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets. While TCE therapeutics have displayed potent anti-tumor activity in hematological cancers, developing TCEs to treat solid tumors have faced challenges due to the limitations of prior TCE technologies, namely (i) overactivation of the immune system leading to cytokine release syndrome, (ii) on-target, healthy tissue toxicities, and (iii) poor pharmacokinetics leading to short half-life. Janux is using its TRACTr platform technology to engineer product candidates designed to overcome these limitations by offering accuracy, stability, activity, modularity, and manufacturability. Janux is developing a broad pipeline with lead TRACTr programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2). Janux is also applying its proprietary technology to develop a TRACIr costimulatory bispecific product candidate against programmed death-ligand 1 (PD-L1) and Cluster of Differentiation 28 (CD28) designed to further enhance the anti-tumor activity of T cells. For more information, please visit www.januxrx.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestors:<\/b>
Andy Meyer
\n
Janux Therapeutics
\n
ameyer@januxrx.com<\/a>
(202) 215-2579\n<\/p>\n

\nMedia:<\/b>
Jessica Yingling, Ph.D.
\n
Little Dog Communications Inc.
\n
jessica@litldog.com<\/a>
(858) 344-8091\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO–(BUSINESS WIRE)–$JANX—Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will participate in a Novel Immuno-Oncology (IO) panel discussion at Cowen’s 43rd … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53912","6":"format-standard","7":"category-industry"},"yoast_head":"\nJanux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/janux-therapeutics-to-participate-in-novel-io-panel-discussion-at-cowens-43rd-annual-health-care-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO–(BUSINESS WIRE)–$JANX—Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will participate in a Novel Immuno-Oncology (IO) panel discussion at Cowen’s 43rd ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/janux-therapeutics-to-participate-in-novel-io-panel-discussion-at-cowens-43rd-annual-health-care-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-14T17:05:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230214005399\/en\/1712872\/21\/Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/janux-therapeutics-to-participate-in-novel-io-panel-discussion-at-cowens-43rd-annual-health-care-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/janux-therapeutics-to-participate-in-novel-io-panel-discussion-at-cowens-43rd-annual-health-care-conference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen’s 43rd Annual Health Care Conference\",\"datePublished\":\"2023-02-14T17:05:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/janux-therapeutics-to-participate-in-novel-io-panel-discussion-at-cowens-43rd-annual-health-care-conference\\\/\"},\"wordCount\":396,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/janux-therapeutics-to-participate-in-novel-io-panel-discussion-at-cowens-43rd-annual-health-care-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230214005399\\\/en\\\/1712872\\\/21\\\/Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/janux-therapeutics-to-participate-in-novel-io-panel-discussion-at-cowens-43rd-annual-health-care-conference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/janux-therapeutics-to-participate-in-novel-io-panel-discussion-at-cowens-43rd-annual-health-care-conference\\\/\",\"name\":\"Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/janux-therapeutics-to-participate-in-novel-io-panel-discussion-at-cowens-43rd-annual-health-care-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/janux-therapeutics-to-participate-in-novel-io-panel-discussion-at-cowens-43rd-annual-health-care-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230214005399\\\/en\\\/1712872\\\/21\\\/Logo.jpg\",\"datePublished\":\"2023-02-14T17:05:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/janux-therapeutics-to-participate-in-novel-io-panel-discussion-at-cowens-43rd-annual-health-care-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/janux-therapeutics-to-participate-in-novel-io-panel-discussion-at-cowens-43rd-annual-health-care-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/janux-therapeutics-to-participate-in-novel-io-panel-discussion-at-cowens-43rd-annual-health-care-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230214005399\\\/en\\\/1712872\\\/21\\\/Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230214005399\\\/en\\\/1712872\\\/21\\\/Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/janux-therapeutics-to-participate-in-novel-io-panel-discussion-at-cowens-43rd-annual-health-care-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen’s 43rd Annual Health Care Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/janux-therapeutics-to-participate-in-novel-io-panel-discussion-at-cowens-43rd-annual-health-care-conference\/","og_locale":"en_US","og_type":"article","og_title":"Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference - Pharma Trend","og_description":"SAN DIEGO–(BUSINESS WIRE)–$JANX—Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will participate in a Novel Immuno-Oncology (IO) panel discussion at Cowen’s 43rd ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/janux-therapeutics-to-participate-in-novel-io-panel-discussion-at-cowens-43rd-annual-health-care-conference\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-14T17:05:15+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230214005399\/en\/1712872\/21\/Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/janux-therapeutics-to-participate-in-novel-io-panel-discussion-at-cowens-43rd-annual-health-care-conference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/janux-therapeutics-to-participate-in-novel-io-panel-discussion-at-cowens-43rd-annual-health-care-conference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen’s 43rd Annual Health Care Conference","datePublished":"2023-02-14T17:05:15+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/janux-therapeutics-to-participate-in-novel-io-panel-discussion-at-cowens-43rd-annual-health-care-conference\/"},"wordCount":396,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/janux-therapeutics-to-participate-in-novel-io-panel-discussion-at-cowens-43rd-annual-health-care-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230214005399\/en\/1712872\/21\/Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/janux-therapeutics-to-participate-in-novel-io-panel-discussion-at-cowens-43rd-annual-health-care-conference\/","url":"https:\/\/pharma-trend.com\/en\/janux-therapeutics-to-participate-in-novel-io-panel-discussion-at-cowens-43rd-annual-health-care-conference\/","name":"Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/janux-therapeutics-to-participate-in-novel-io-panel-discussion-at-cowens-43rd-annual-health-care-conference\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/janux-therapeutics-to-participate-in-novel-io-panel-discussion-at-cowens-43rd-annual-health-care-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230214005399\/en\/1712872\/21\/Logo.jpg","datePublished":"2023-02-14T17:05:15+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/janux-therapeutics-to-participate-in-novel-io-panel-discussion-at-cowens-43rd-annual-health-care-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/janux-therapeutics-to-participate-in-novel-io-panel-discussion-at-cowens-43rd-annual-health-care-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/janux-therapeutics-to-participate-in-novel-io-panel-discussion-at-cowens-43rd-annual-health-care-conference\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230214005399\/en\/1712872\/21\/Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230214005399\/en\/1712872\/21\/Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/janux-therapeutics-to-participate-in-novel-io-panel-discussion-at-cowens-43rd-annual-health-care-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen’s 43rd Annual Health Care Conference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53912","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53912"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53912\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53912"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53912"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53912"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}